Oramed Pharmaceuticals (ORMP) Earnings Date, Estimates & Call Transcripts $2.20 -0.03 (-1.35%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals Earnings Summary Upcoming Q1 Earnings DateMay. 8Before Market OpensEstimatedConsensus EPS (Mar. 27) -$0.03 Actual EPS (Mar. 27) $0.01 Beat By $0.04 Oramed Pharmaceuticals issued Q4 2024 earnings on March 27, 2025, reporting an EPS of $0.01, which topped analysts' consensus estimates of -$0.03 by $0.04. With a trailing EPS of -$0.21 and a P/E Ratio of 20.00, Oramed Pharmaceuticals' earnings are expected to decrease next year, from ($0.03) to ($0.19) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportORMP Upcoming EarningsOramed Pharmaceuticals' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules. Get Oramed Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataORMP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ORMP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Oramed Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.05-$0.01-$0.03Q2 20252-$0.06-$0.01-$0.04Q3 20252-$0.07-$0.01-$0.04Q4 20252-$0.08-$0.03-$0.06FY 20258($0.26)($0.06)($0.16) Remove Ads Oramed Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/8/2025(Estimated)--------3/27/2025Q4 2024-$0.03$0.01+$0.04$0.01--8/14/2024Q2 2024$0.01$0.22+$0.21$0.22--5/9/2024Q1 2024$0.02$0.04+$0.02$0.04--3/6/2024Q4 2023-$0.12-$0.08+$0.04-$0.49--11/9/2023Q3 2023-$0.09-$0.08+$0.01-$0.08--8/10/2023Q2 2023-$0.11-$0.03+$0.08-$0.03$0.70M$0.67M5/11/2023Q1 2023-$0.23-$0.08+$0.15-$0.08$0.75M$0.67M Oramed Pharmaceuticals Earnings - Frequently Asked Questions When is Oramed Pharmaceuticals's earnings date? Oramed Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based off last year's report dates. Learn more on ORMP's earnings history. Did Oramed Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Oramed Pharmaceuticals (NASDAQ:ORMP) reported $0.01 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.03) by $0.04. Learn more on analysts' earnings estimate vs. ORMP's actual earnings. How much revenue does Oramed Pharmaceuticals generate each year? Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded annual revenue of $1.34 million. How much profit does Oramed Pharmaceuticals generate each year? Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded net income of $5.53 million. ORMP has generated -$0.21 earnings per share over the last four quarters. What is Oramed Pharmaceuticals's price-to-earnings ratio? Oramed Pharmaceuticals (NASDAQ:ORMP) has a trailing price-to-earnings ratio of 20.00. What is Oramed Pharmaceuticals's EPS forecast for next year? Oramed Pharmaceuticals's earnings are expected to decrease from ($0.03) per share to ($0.19) per share in the next year. More Earnings Resources from MarketBeat Related Companies Eton Pharmaceuticals Earnings Verve Therapeutics Earnings ORIC Pharmaceuticals Earnings Tourmaline Bio Earnings Kamada Earnings Rapport Therapeutics Earnings Altimmune Earnings Autolus Therapeutics Earnings Erasca Earnings SNDL Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s Next Remove Ads This page (NASDAQ:ORMP) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts